PDE4A and chronic obstructive pulmonary disease: In human ASM cells, PDE4 has been found to be the major PDE subtype that is involved in cAMP degradation [17] and PDE4 inhibitors such as roflumilast and cilomilast have been developed recently, in particular for the treatment of COPD.